Latest news with #Padcev
Yahoo
30-04-2025
- Business
- Yahoo
Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth
Revenue: $13.7 billion, a decline of 6% operationally. Diluted EPS: $0.52 per share. Adjusted Diluted EPS: $0.92 per share. Adjusted Gross Margin: Approximately 81%. Total Adjusted Operating Expenses: $5.2 billion, a 12% decline operationally. Adjusted SI&A Expenses: Decreased 12% operationally. Adjusted R&D Expenses: Decreased 12% operationally. Dividend Returned to Shareholders: $2.4 billion. Internal R&D Investment: $2.2 billion. Full-Year 2025 Revenue Guidance: $61.0 to $64.0 billion. Full-Year 2025 Adjusted Diluted EPS Guidance: $2.80 to $3.00. Warning! GuruFocus has detected 6 Warning Signs with PFE. Release Date: April 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Pfizer Inc (NYSE:PFE) reported strong financial performance in Q1 2025, with a focus on improving operating margins and cash flow. The company is advancing its R&D pipeline with multiple anticipated milestones, including regulatory decisions and Phase 3 readouts. Pfizer Inc (NYSE:PFE) is expanding its commercial portfolio, with significant growth in key products like Vyndaqel, Nurtec, and Padcev. The company is committed to maintaining and growing its dividend, reinforcing its capital allocation strategy. Pfizer Inc (NYSE:PFE) is leveraging digital tools and automation to achieve significant cost savings, aiming for $7.7 billion in savings by 2027. Pfizer Inc (NYSE:PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design. The company faces challenges from competition in the market, particularly impacting the Vyndaqel family of products. There is uncertainty regarding potential tariffs, which could impact Pfizer Inc (NYSE:PFE)'s financial performance and manufacturing strategy. The discontinuation of the danuglipron program in the obesity portfolio highlights challenges in R&D prioritization. Pfizer Inc (NYSE:PFE) is navigating a complex global landscape with evolving trade and tariff policies, which could affect future operations. Q: Can you reinforce your commitment to maintaining and growing the dividend, especially with tariff uncertainties and potential impacts on cash flows? A: David Denton, CFO, emphasized that the dividend remains a critical component of Pfizer's capital allocation strategy. The company is focused on improving operating margins and cash flow yield to support all capital allocation priorities, including the dividend. Q: What are your expectations for the COVID business this year, considering the nuances around Paxlovid and vaccine sales? A: Aamir Malik, Chief US Commercial Officer, explained that Paxlovid utilization trends closely follow infection rates, with a 50% treatment rate and 80% fulfillment rate. The company expects multiple COVID waves this year and has set up a model to transition Medicare patients to a traditional model. Alexandre De Germay, Chief International Commercial Officer, added that Comirnaty performed well internationally, and Pfizer is preparing for vaccination campaigns in the Southern Hemisphere. Q: What are the key aspects you are looking for in a potential obesity asset, following the discontinuation of danuglipron? A: Chris Boshoff, Chief Scientific Officer, stated that Pfizer remains committed to obesity and is advancing its pipeline of differentiated oral medicines, including a GIPR antagonist in Phase 2. The focus is on tolerability, accessibility, and convenience, with an emphasis on personalized combinations addressing specific diseases associated with obesity. Q: How is Pfizer engaging with the 232 investigation on tariffs, and what is your best sense of timing for more information from the Administration? A: Albert Bourla, CEO, explained that the 232 investigation is focused on national security concerns related to the pharmaceutical supply chain. Pfizer is engaging with the Administration and is cautiously optimistic about the outcome. The investigation is expected to be completed within 270 days, but the Administration may work faster. Q: Can you provide more details on Pfizer's cost realignment program and its impact on 2025? A: David Denton, CFO, mentioned that Pfizer is on track to achieve $4.5 billion in savings by the end of 2025, with an additional $1.2 billion in savings expected by 2027. The focus is on improving productivity and operational efficiency, with some savings realized in 2025 and more in the following years. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
Pfizer profits dip on lower Paxlovid sales
Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects. Sales of Paxlovid slid 75 percent amid lower Covid-19 infections and reduced government purchases of the medication. But Pfizer scored higher revenues for its Covid-19 vaccine, along with some other products, including the heart medication Vyndaqel and the cancer drug Padcev. Profits in the first quarter fell five percent to $3.0 billion, while revenues dropped eight percent to $13.7 billion. Pfizer Chief Executive Albert Bourla said the company's discontinuation earlier this month of the Danuglipron obesity drug was the right call after a participant in a trial experienced a liver injury that cleared up after the treatment was stopped. Pfizer is developing other medications in the obesity and related areas and could pursue "external opportunities" such as partnerships or acquisitions, Bourla said. Pfizer is also working on treatments for a number of other ailments, including bladder cancer and multiple myeloma, Bourla said. "We are on track for a strong year of anticipated pipeline catalysts," he said. The drugmaker maintained its full-year sales forecast of between $61-64 billion. In 2024, Pfizer's revenues were $63.6 billion. The projection "does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time," Pfizer said. Pfizer said it is on track to deliver $4.5 billion in cost savings through the end of 2025. It also is implementing a reorganization of its research and development, and a manufacturing "optimization" program. Shares rose 0.5 percent in pre-market trading. jmb/aha Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
Pfizer reports mixed results in first quarter earnings, reiterates 2025 outlook
Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer reported adjusted earnings per share (EPS) of $0.92, beating Wall Street expectations of $0.66 per share. Revenue came in at $13.7 billion, compared to the consensus of $14 billion. The stock was up less than 1% in premarket trading on Tuesday. Read more about Pfizer's stock moves and today's market action. "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment," CEO Albert Bourla said in a statement Tuesday. The company previously signaled savings of $6 billion through cost-cutting, and increased that to $7.7 billion Tuesday. Pfizer is one of the large-cap pharma companies in focus for investors as it faces patent cliffs for top blockbusters by the end of the decade. Investors have been waiting and watching as COVID-19 revenues wane for the company to right-size operations and find new products in its pipeline — both internal and acquired — to fill a $17 billion revenue hole. Bourla has previously said his recent flurry of deals, including the $43 billion for Seagen and its oncology pipeline, were executed to fill that revenue hole. One drug alone, Padcev, is expected to add $3.1 billion annually. In 2024, it contributed $1.6 billion. One hope had been the company's entry into the obesity space, dominated by Eli Lilly (LLY) and Novo Nordisk (NVO). Pfizer had been viewed as one of the key contenders in the near term for Lilly and its oral version of the weight-loss drugs, which are currently in injectable form. But this month, Pfizer had to halt its late-stage trial due to a liver injury in one patient. Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
France 24
29-04-2025
- Business
- France 24
Pfizer profits dip on lower Paxlovid sales
Sales of Paxlovid slid 75 percent amid lower Covid-19 infections and reduced government purchases of the medication. But Pfizer scored higher revenues for its Covid-19 vaccine, along with some other products, including the heart medication Vyndaqel and the cancer drug Padcev. Profits in the first quarter fell five percent to $3.0 billion, while revenues dropped eight percent to $13.7 billion. Pfizer Chief Executive Albert Bourla said the company's discontinuation earlier this month of the Danuglipron obesity drug was the right call after a participant in a trial experienced a liver injury that cleared up after the treatment was stopped. Pfizer is developing other medications in the obesity and related areas and could pursue "external opportunities" such as partnerships or acquisitions, Bourla said. Pfizer is also working on treatments for a number of other ailments, including bladder cancer and multiple myeloma, Bourla said. "We are on track for a strong year of anticipated pipeline catalysts," he said. The drugmaker maintained its full-year sales forecast of between $61-64 billion. In 2024, Pfizer's revenues were $63.6 billion. The projection "does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time," Pfizer said. Pfizer said it is on track to deliver $4.5 billion in cost savings through the end of 2025. It also is implementing a reorganization of its research and development, and a manufacturing "optimization" program.
Yahoo
29-04-2025
- Business
- Yahoo
Pfizer reports mixed results in first quarter earnings, reiterates 2025 outlook
Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer reported adjusted earnings per share (EPS) of $0.92, beating Wall Street expectations of $0.66 per share. Revenue came in at $13.7 billion, compared to the consensus of $14 billion. The stock was up less than 1% in premarket trading on Tuesday. Read more about Pfizer's stock moves and today's market action. "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment," CEO Albert Bourla said in a statement Tuesday. Pfizer is one of the large-cap pharma companies in focus for investors as it faces patent cliffs for top blockbusters by the end of the decade. Investors have been waiting and watching as COVID-19 revenues wane for the company to right-size operations and find new products in its pipeline — both internal and acquired — to fill a $17 billion revenue hole. Bourla has previously said his recent flurry of deals, including the $43 billion for Seagen and its oncology pipeline, were executed to fill that revenue hole. One drug alone, Padcev, is expected to add $3.1 billion annually. In 2024, it contributed $1.6 billion. One hope had been the company's entry into the obesity space, dominated by Eli Lilly (LLY) and Novo Nordisk (NVO). Pfizer had been viewed as one of the key contenders in the near term for Lilly and its oral version of the weight-loss drugs, which are currently in injectable form. But this month, Pfizer had to halt its late-stage trial due to a liver injury in one patient. Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
